High-dose therapy with autologous marrow or peripheral blood stem cell (PBSC) rescue has been extensively applied in the treatment of multiple myeloma (MM) patients during the past 10 years resulting in improved event-free and overall survival when compared with standard chemotherapy. However, relapses are common and cure is unlikely in the majority of patients. Because both bone marrow and PBSCs are contaminated with myeloma cells it is conceivable that relapse after autotransplantation originates at least in part from autografted tumor cells. In this study, mobilized PBSCs were examined for the presence of myeloma cells based on immunophenotyping and sensitive polymerase chain reaction (PCR)-based techniques. In addition, CD34+ Lin-Thy+ stem cells were purified from mobilized PBSC harvests of 10 MM patients by sequentially using counterflow elutriation centrifugation, treatment with phenylalanine methylester, and flow sorting, using 5-parameter gating (propidium iodide, forward scatter, side scatter, CD34+ Y Lin-and CD34+
UTOLOGOUS TRANSPLANTATION is now frequently used in the treatment of patients with multiple myeloma (MM).'" A major advance in autologous transplantation was the observation that peripheral blood stem cells (PBSCs), mobilized with robust doses of high-dose cyclophosphamide andor hematopoietic growth factor, markedly shortened the duration of bone marrow (BM) aplasia after myeloablative Since 1990, transplant protocols with PBSC support have been used for MM patients at our institution and elseto 50% complete remission (CR) rate in newly diagnosed MM2".7 and a 10% to 20% CR rate in refractory di~ease.'~ A French prospective randomized study, including 200 newly diagnosed MM patients, showed a significantly better CR rate and event-free and overall survival with autotransplants when compared with standard chemotherapy." However, relapse remains a problem especially in high-risk patient^.^.'"^ Although the morphologically recognizable MM cells are mainly restricted to the BM, clonal tumor cells have been detected in the peripheral blood based on DNA aneuploidy, light-chain restriction, Ig gene rearrangement and polymerase chain reaction (PCR) for the hypervariable region of the heavy chain.'"" Immunophenotyping of these cells showed weak expression of CD19 and CD20, moderate positivity of CD10, PCA-1 and CD56, and strong reactivity with antibodies to CD45RO and CD38.'6-23 A proportion of the circulating MM cells expresses the MDR gene.24 Therefore, PBSC infusions may contribute to relapse after transplantation. Supporting evidence for the role of the autograft as a potential source of relapse comes from reports in lymphoma, neuroblastoma, and breast cancer showing that the rate of relapse correlates with the presence of occult tumor cells in the marrow or in the peripheral blood. In these studies, gene marking of the autologous marrow ~e l l s ,~~,~~ sensitive immunocytochemical or PCR-based were applied. To detect minimal contamination with myeloma cells, a PCR assay was developed based on the patient-specific DNA sequence corresponding to the CDRIII region of the rearranged Ig heavy chain, thus providing a marker for detection of clonal B Consensus oligonucleotide primers can be used to PCR-amplify the CDRIII region of the rearranged heavy chain and to detect the presence of small amounts of clonal B cells (1 clonal B-cell in a background of 105 normal cells).
Herein, we describe the purification of CD34+ Lin-Thy+ stem cells from PBSC harvests of 10 MM patients, after treatment with high-dose cyclophosphamide and granuloytemacrophage colony-stimulating factor (GM-CSF). Although present in large quantities in virtually all unsorted PBSC, using flow cytometry and quantitative PCR, myeloma cells were undetectable in purified CD34+ Lin-Thy+ stem cells. SySternix) and for Thy (CD,C)O) (followed by Thy-biotin-streptavidin and tinally by biotin-PE, SyStemix). Isotypic controls wcre used to determine the background staining o f rcd versus green lluorescence (CD34'/Thy' stem cclls versus L i n cells). Propidium iodide (PI) was not used for stem ccll sorting. Ccll sorting was performed by tlsing a fuorescencc-activalcd cell sorter (P'ACS; model Vantage,
MATERIALS AND METHODS
The ph~worypic t -c , / n f i o n t h i p h&w?n ('l).iX""''", DNA rxtrudoJt DNA was extracted from llow sorted C:D3X""F1" CD4S1"" BM plasma cells (, > 1 0 0 , 0 0 0 ) using the DNA micro-extraction kit from Stratagene (La Jolla, CA) according to the manuPacturer's instructions. Extraction of DNA from nonsortcd peripheral blood mononuclear cells (IO" cell), or from flow-sortcd CD34' Lin Thy (IO") or CD34' Lin Thy ' cclls (0.5 t o I X IO") was perlormcd as described above for purilicd plasma cell\. DNA quantitation was done spectropholonlctl. . 50 mmol/L KC1 and I .2 mmol/L MgCI2. Two consecutive amplification protocols were used: 5 minute denaturation at 94°C followed by 5 cycles of 30 seconds at 94°C 30 seconds at 45"C, and 1 minute at 74°C. This protocol was followed by 30 cycles of 30 seconds at 94°C. 1 minute at 53°C. and 2 minutes at 74°C. One fifth of the reaction mixture (10 pL) was run on 6% polyacrylamide gels (BioRad minigels; BioRad, Hercules, CA).& Bands corresponding to the CDRIII fragments were identified by staining of gels with ethidium bromide and bands were eluted from the gel by the crush-and-soak method.'" Purified DNA fragments were used for sequencing.
DNA sequencing and synthesis of the allele-specific (ASO) primer. DNA sequencing was performed by the dideoxy termination method in an automated sequencing system (model 373A; Applied Biosysterns, Foster City, CA), using cycle sequencing with fluorescentlabeled JH primer and the allele-specific CDRIII fragment (Applied Biosystems labeling kit). After sequencing, the AS0 primer was designed by deducing the CDRlIl sequence using a published sequence of the human Ig heavy chain gene.4R Synthesis of the AS0 primer oligonucleotide (15 to 19 bp) was performed by automated DNA synthesis system (Applied Biosystems, Foster City, CA), with over 99% purity of the product.
ASO-PCR for residual myeloma cells in sorted and nonsorted peripheral blood samples.
To generate an ASO-PCR dilution curve, genomic DNA from pure plasma cells was diluted in 0.5 pg of normal peripheral blood DNA in log dilution intervals (10% to 0.001% plasma cell DNA). Tubes with DNA from sorted and nonsorted cells (0.5 pg) were also run using the Perkin Elmer Cetus 
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L KCI, 1.2 mmol/L MgC12, 2.5 U of Taq polymerase and 5 to I O pCi of '2P-deoxycytidine triphosphate ("P-dCTP; NEN, Boston, MA). After a denaturation step (5 minutes at 95°C). amplification was performed by 30 cycles of 30 seconds; at 95", 30 seconds; at 56°C. 45 seconds; at 75°C. followed by 10 minutes; at 75°C. for extension of the PCR products. The labeled products were then separated on a polyacrylamide gel as before. Gels were dried and exposed for I to 3 hours to x-ray film (Fuji RX GCU film; Fuji Photo film, Tokyo, Japan) in a Fisher Biotech cassette with L plus intensifying screens (Fisher Biotech, Pittsburgh, PA). Quantitation was done by scanning of developed x-ray films using a computing densitometer model 300A equipped with image quantitation program (Molecular Dynamics, Sunnyvale, CA). The actual percentage of contaminating myeloma cells in patients samples was extrapolated from a dilution curve made separately for each patient. The correlation coefficients for the logllinear regression (linear density versus log dilution) for the 10 patients studied ranged between r = .87 and r = .99. Individual extrapolations were calculated between adjacent dilution points. The specificity of the AS0 primers was confirmed by crossing primers of different patients. Amplification of the CDRllI band was observed only when a proper primer used for the corresponding patient. Furthermore, in three cases, the band amplified in the ASO-PCR reaction was sequenced and was found to contain identical sequence to the original CDRIII fragment. Figure IA shows the relative paucity of CD38'nsh'CD56+ (0.9% of the lymphoblastoid gated region) and CD38'nph'CD56-cells (0.5%) in the apheresis sample from a patient with non-Hodgkin's lymphoma, whereas in a patient with MM high levels of both CD38'nEh1CD56+ (5.8%) and CD38'ngh'CD56-(IO. 1 %) cells were present. Mobilized PBSC of 5 additional MM patients showed percentages of CD38'nghh' CD56' cells ranging from 1.0 to 6.3% (average, 4.8%) and of CD38h"8h' CD56-cells from 0.7% to 10.1% (average, 3.6%). Calculated for the total number of cells (3 x IOx to 9 x IO9), 2 x IO3 to 8 x IO' CD38b"Eh' cells were present in a single PBSC collection. At least 45% of these CD38'nsh' cells expressed the same heavy and light chain as the BM plasma cells.
RESULTS

Plasma cells (CD38h"""CD56+") in P B X harvests of
MM patients do not overlap with hematopoietic stem cells (CD34' Lin-Thy').
The phenotypic relationship between CD34' Lin-Thy' stem cells and CD38h"eh'CD56'" myeloma cells was examined by 7-parameter flow cytometric analysis (Fig 2, A  through F) . Color gating was used to distinguish each cell population in the multiple analyses. Thy' and CD34' cells express the CD38 antigen only weakly (Fig 2, B and C) and are negative for the CD56 antigen (Fig 2, D and E) . CD34' Lin-Thy' cells can be completely separated from CD38b"ghh' CD56'" cells ( Fig 2F) . Flow-sorted CD34' Lin-Thy' cells were restained with CD38 FITC or CD56 FITC (Fig 2, G through L) . The percentages of CD38h"8hh' CD56' or CD38'"ph' CD56-cells calculated from the original PBSC harvest were (0. l %), similar to the background level of staining obtained with isotypic controls (<O. 1 %).
Purification of CD34+ Lin-Thy' stem cells by Jlow sorting. Samples from each purification step were analyzed for the presence of CD34' Lin-Thy' cells to evaluate the relative purity of the stem cell preparations. A representative analysis of one patient is shown in Fig 3. After apheresis, elutriation, PME treatment and flow sorting, the total cell numbers were 2.2 X IO", 6.8 X 10'. 4.2 X I O ' , and 1.1 X lo', respectively; the percentages of CD34' Lin-cells were 3.4, 8.2, 20, and 94; and the percentages of CD34' LinThy' cells were 0.9, 2.7, 9.3, and 88, respectively. Cell viability was checked after each of the above outlined purification steps and was greater than 95%.
The average recovery of stem cells from all of the enrichment steps up to the flow-sort was 65%. The average recovery from the flow-sort was 60%, hence the average overall recovery was about 40%. This overall recovery is comparable with the recovery obtained by other methods such as the GAZllT ET AL immunomagnetic beads and the avidin columns. Factors that did affect the recovery of stem cells were the degree of contamination with red blood cells and extent of prior therapy (results not shown). However, no special effort was done in these studies to improve the yield of stem cells. Careful selection of patients and apheresis collections should result in an improved recovery of stem cells for clinical trials. However, it is important to note that the shipment of the PBSC harvests per se, did not result in loss of stem cells, and only modest decrease in granulocytes was observed (10% to 15%, results not shown). From the flow analysis, it is clear that the CD34' Lin-Thy' stem cell population was free of myeloma cells to the sensitivity of 0.1% (the background staining of the isotypic controls). To test for lower levels of contamination, we used the PCR-based amplification of the CDRIII region. This method results in a sensitivity of 0.001% myeloma cells (see below).
Amplification of the CDRIII region by PCR with consensus primers. Amplification by PCR of the CDRIII region of the Ig heavy chain was achieved using JH and FR3 consensus primers that resulted in DNA fragments of 70 to 90 bp. Representative examples of the CDRIII bands derived from genomic DNA of sorted plasma cells from seven patients are depicted in Fig 4. DNA from one patient (lane 1; R.J.) was extracted from a nonsorted population of plasma cells (< 10%) and two bands were amplified. In this case, the lower band gave the proper sequence for the AS0 primer. PCR products obtained from genomic DNAs of unsorted ( Fig 5A) and flow-sorted CD34+ Lin-Thy+ PBSC (Fig 5B) . The dilution curve for each patient is displayed. The level of contamination in all purified stem cell samples was below 1 clonal B cell in lo5 sorted cells. Log linear regression was performed on the values obtained from the four last dilutions of each patient's DNA sample (1% to 0.001% plasma cells). The calculated log depletion of clonal B cells varied from more than 2.7 to greater than 6.5 (Table 1) .
In 6 patients, the presence of residual clonal B cells was determined in both CD34+ Lin-Thy+ and CD34' Lin-Thycells. As shown in Fig 6, the level of contamination was less than l clonal B cell in both lo5 CD34+ Lin-Thy+ (B) and CD34+ Lin-Thy-cells (C).
The calculated number of residual clonal B cells in the CD34+ Lin-Thy+ cells of the 10 patients analyzed was between less than 1 and less than 312 cells in a PBSC collection of 6 X 10' to 9 X lo9 total cells (Table 1) . Recoveries of both CD34+ Lin-Thy' and CD34+ Lin-Thy-cells were between 3.5 X lo5 and 3.1 X lo7 cells, with an input between 8.4 X 10' and 89.7 X 10' apheresed PBSC.
DISCUSSION
This study shows the feasibility of purification of an early hematopoietic progenitor cell population (CD34+ LinThy') from mobilized PBSC harvests of MM patients as a means to markedly deplete clonal B cells.
Mobilized PBSC of MM patients contained between 0.1 % to 10% myeloma cells expressing CD38nght CD56+", previously shown to be present on circulating MM cells.23 No overlap was observed on flow cytometry between MM cells (CD3gtight CD56+") and stem cells (CD34+ Lin-Thy'). In contrast with MM cells, flow-sorted CD34'
Lin-Thy+ cells stain only weakly for the CD38 antigen and are negative for CD56.
Conventional flow-sorting is a slow and labor-intensive procedure. Therefore, it was essential to remove accessory cells to reduce sorting time and increase the purity of the final preparations. Debulking was accomplished by counterflow elutriation centrifugation and treatment with PME, resulting in a depletion greater than 99% of Lin' cells within 3 hours. CD34' Lin-Thy' cells were enriched from 0.9% in the initial PBSC collection to 88% post flow-sorting. These cells appeared fully viable49 and gave rise to all hematopoietic lineages in various in vivo and in vitro stem cell assays.50 PCR amplification of the CDRIII sequence has been applied to quantitate minimal residual disease in various Bcell malignancies, including
We used this technique to quantitate residual clonal B cells in the final stem cell preparation. The consensus (JH, FR3) primer amplification reaction, performed with DNA from highly purified (>90%) flow-sorted plasma cells (CD38bnght CD453, was successful in over 80% of cases attempted. Flow-sorted CD3gb"ph' CD56' myeloma cells from PBSC collections containing greater than 45% light-chain restricted B cells, were also successfully used to amplify the CDRIII band.
Residual clonal B cells in the final stem cell preparations were quantitated using flow cytometry and ASO-PCR. The level of detection of minimal residual disease with flow cytometry is limited (0.1%). By flow cytometry, all PBSC collections were negative for myeloma cells; however, 6 of 10 collections contained significant amount of meloma cells by the ASO-PCR technique. In all 10 cases, a log depletion of clonal B cells by greater than 2.7 was obtained with less than 1 clonal B cell detectable in lo5 stem cells (CD34+ Lin-Thy+). However, it is important to note that not all the dilution curves were linear for all 5 logs of dilution; in some cases, linearity was limited to the last 3 logs of dilution. Therefore, the limit of sensitivity is about 1 clonal B cell in 10' cells and the accuracy of our measurements may be off by one-half log. Based on this technique, unsorted mobilized PBSC harvests contained variable numbers of clonal B cells (0.001% to 10%). In the purified fractions a greater depletion of clonal cells (up to 7 logs) was obtained in patients with a higher initial load of tumor cells (0.1% to 10%).
The procedure described herein results in highly purified preparations of CD34+ Lin-Thy' stem cells (88%). Such a degree of purity could not be achieved with other available CD34 selection methods (40% to 80%), using avidin biotin immunoadsorbent magnetic micro sphere^?^ or monoclonal antibodies covalently immobilized on polystyrene surfaces.54 Furthermore, these CD34+ cells exhibit a lineage ~ommitment.~~ CD19 coexpression has been reported on 40% to 60% of CD34+ cells in the peripheral blood of MM patients.56 More importantly, the majority of these CD34+ CD19+ cells belongs to the malignant clone, based on DNA aneuploidy" and CDRIII PCR,s6,s7 and show the same N-ras mutation as the malignant plasma cells in the BM,5' although diploid myeloma cells expressing the CD19 antigen were described.59 Hence, selection only for CD34' expression is unlikely to provide tumor-free grafts.
Our study has not addressed the important practical aspects of collecting, in a timely manner, adequate numbers of CD34+ Lin-Thy' stem cells to ensure engraftment. The availability of a high-speed fluorescence-activated cell sorter, processing up to 20,000 cellshecond, makes it feasible to complete the clinical sorting step within 2 to 3 hours, with an overall processing time of 7 to 8 hours.60 Engraftment has been reported with as few as 0.27 to 0.6 X lo6 cellskg CD34 cells with an average purity of 42% and 62%, Approximately 25% of CD34+ cells are CD34+ Lin-Thy+.37 Therefore, 2 X 105/kg of CD34' Lin-Thy+ cells should be sufficient to ensure complete engraftment after myeloablative therapy. Hence, the total number of CD34+ Lin-Thy+ stem cells necessary for one transplant will vary between 1 X lo7 and 2 X lo7 cells (assuming body weight of 50 to 100 kg) with a maximum number of MM cells infused of less than 200.
The presence of between 1% and 15% CD34+Thy+Lin-cells in mobilized PBSC,62,63 suggests that enough stem cells can be collected for two autotransplants in patients with limited prior exposure to stem cell-damaging alkylating agents. 64 Finally, the stem cell purification technique outlined in this paper should also provide tumor-free grafts in low-grade B-cell lymphoma and B-cell chronic lymphocytic leukemia.
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